Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum to Present at Two Healthcare Conferences in November

HOUSTON--(BUSINESS WIRE)--Nov. 2, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that Tom Farrell, President and CEO, will present a corporate overview at two healthcare investor conferences in November.

24th Annual Credit Suisse Healthcare Conference

  • Location: The Phoenician, Scottsdale, AZ
  • Presentation Date: Tuesday, November 10, 2015
  • Presentation Time: 11:00 a.m. MST (1 p.m. EST)

Jefferies 2015 Global Healthcare Conference

  • Location: The May Fair Hotel, London, UK
  • Presentation Date: Thursday, November 19, 2015
  • Presentation Time: 2:00 p.m. GMT (9:00 a.m. EST)

The presentations will be webcast live and may be accessed from the News & Events section of the Bellicum website. Archived versions of the webcasts will be available for replay for at least two weeks following the events.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals, Inc.

Investors:
Bellicum Pharmaceuticals
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com